Novavax, Inc. (NASDAQ:NVAX) Director James F. Young Sells 4,600 Shares

Novavax, Inc. (NASDAQ:NVAX) Director James F. Young sold 4,600 shares of the stock in a transaction that occurred on Tuesday, December 24th. The shares were sold at an average price of $8.48, for a total transaction of $39,008.00. Following the transaction, the director now owns 57,160 shares in the company, valued at approximately $484,716.80. This trade represents a 7.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Novavax Price Performance

Shares of NASDAQ NVAX traded up $0.53 during mid-day trading on Thursday, reaching $8.57. The company’s stock had a trading volume of 3,813,721 shares, compared to its average volume of 9,060,255. Novavax, Inc. has a 52 week low of $3.53 and a 52 week high of $23.86. The firm has a market capitalization of $1.37 billion, a PE ratio of -3.79 and a beta of 2.02. The stock has a fifty day moving average of $8.74 and a two-hundred day moving average of $11.40.

Novavax (NASDAQ:NVAX) last released its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.07. The firm had revenue of $84.51 million during the quarter, compared to the consensus estimate of $65.80 million. During the same period in the previous year, the firm earned ($1.26) EPS. The business’s revenue was down 54.8% compared to the same quarter last year. Analysts anticipate that Novavax, Inc. will post -1.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on NVAX. B. Riley reissued a “buy” rating and set a $26.00 price objective (up previously from $23.00) on shares of Novavax in a research report on Thursday, October 10th. Jefferies Financial Group reduced their price target on Novavax from $31.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, October 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $19.00 price objective on shares of Novavax in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $17.83.

Institutional Investors Weigh In On Novavax

Hedge funds and other institutional investors have recently made changes to their positions in the company. Banque Cantonale Vaudoise lifted its stake in shares of Novavax by 500.0% during the 2nd quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 2,500 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of Novavax by 26.9% in the second quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 1,036 shares during the period. Signaturefd LLC boosted its holdings in shares of Novavax by 214.5% in the second quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 3,874 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Novavax by 38.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 1,598 shares in the last quarter. Finally, Midland Wealth Advisors LLC purchased a new position in Novavax during the 2nd quarter worth $152,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.